| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $ | – | |
Sells | $ | – |
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Over the last 12 months, insiders at Evoke Pharma, Inc. have bought $undefined and sold $undefined worth of Evoke Pharma, Inc. stock.
On average, over the past 5 years, insiders at Evoke Pharma, Inc. have bought $0 and sold $48,032 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $1.18M was made by LVP GP III, LLC (10 percent owner) on 2018‑08‑20.
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |